More Karmic Cumuppance, For Martin Shkreli... And Great News,Tonight, Out Of Humanigen.

Again, the study is just getting underway, but this is a very important validation -- that Gilead, and its admittedly leading Remdesivir program for COVID-19 therapies. . . is being jointly trialed with Humanigen's Lenz-. . . it must be very gratifying for Dr. Durrant, and his team.

One bad result, and the whole circus will have to fold its tents, and hop a train out of town -- but for now, they are playing. . . Madison Square Garden. And the shows are. . . sold out.

In truth, quite a nice karmic turnaround, from Martin Shkreli's long-ago debauchery (of its former entity's life science programs, on unrelated agents). Here's the bit, tonight:

. . . .Humanigen, trading for 46 cents per share as recently as mid-March, announced Monday afternoon that its lenzilumab will be tested in combination with remdesivir in NIAID’s Big Effect Trial, effectively categorizing it as a high-priority Covid-19 therapeutic candidate. . .

Some times, the good guys do indeed win out -- eventually. And this may be one of those stories. Do stay tuned.

Onward.

नमस्ते